Sci-Tech Innovation Board Medical ETF Huaxia Gains Over 2.2%, Driven by Policy Tailwinds and Overseas Licensing in Innovative Drug Sector

Industry
โดย Jiemian·Read original
Summary · why it matters

The Sci-Tech Innovation Board Medical ETF Huaxia closed up 2.22% at 1.06 yuan, while the underlying SSE STAR Market Biomedical Index surged 2.38%. Among constituents, Medicilon rose 12.77%, Olymvax Biopharmaceuticals gained 11.54%, and YD Bio advanced 8.49%. Recent policy tailwinds continue to unfold, including optimized review and approval for cell and gene therapies and the initial inclusion of drugs in medical insurance and commercial insurance catalogues. Meanwhile, domestic innovative drug overseas licensing deals approached 100 billion US dollars in the first half of the year, blockbuster new drugs received intensive approvals, and some pharmaceutical companies reported positive half-year earnings forecasts, steadily improving industry fundamentals. Donghai Securities noted that the pharmaceutical and biomedical sector offers significant medium- to long-term investment value and recommended active positioning.

Impact on stocks 4

Others▲ · 4 stocks
Shanghai Medicilon Inc
688202
▲ PositiveDemandrelevance

Overseas licensing deals and positive half-year earnings forecasts improve industry fundamentals, benefiting Medicilon as a constituent.

© 2026 MarketDXNews